A Agilent Technologies Inc.

Agilent Technologies Board of Directors Elects Koh Boon Hwee as New Chairman

Agilent Technologies Inc. (NYSE: A) today announced that Koh Boon Hwee has been elected chairman of the board, effective at the end of today’s shareholders’ meeting. Koh, who has been a member of Agilent’s board since 2003, replaces James G. Cullen, who served as chairman since 2005 and will continue as a director.

“Boon Hwee has provided consistently strong leadership and guidance, both as a board member and as chairman of our compensation committee,” Cullen said. “He has tremendous expertise in international business and a strong commitment to Agilent’s success, making him a valuable asset to the board. I am delighted that he will assume the chairmanship of the company.”

Cullen added, “The orderly transition of the chairman’s role reinforces Agilent’s good-governance practices, including succession planning to ensure consistently extraordinary capability and integrity at the head of our company.”

A proven visionary and distinguished leader, Koh has served as chairman of well-known companies such as Singapore Airlines, Singapore Telecom and DBS Bank, Ltd.

Agilent President and CEO Mike McMullen said, “Boon Hwee is highly respected by both board members and Agilent leadership. He offers a wide breadth of valuable perspective from his leadership at many international and Asia-based companies.”

“I would also like to pay special tribute to Jim Cullen for his exceptional leadership as board chairman over the past 12 years. His guidance and support have been invaluable in the company’s successful transformation into a global leader focused on life sciences, diagnostics and applied chemical markets,” McMullen said. “I appreciate the strength of our board and the diverse insights they bring as Agilent continues to deliver on our priority of supporting our customers with answers they can count on to solve their greatest challenges.”

“I am very pleased to accept the position of chairman during such an important time in the company’s growth,” Koh said. “I am particularly honored to follow Jim Cullen, whose wise counsel and stalwart support over the past decade have helped Agilent develop into a company that now consistently outgrows its competitors. I have long admired Agilent’s scientific contributions, as well as its distinctive customer-centric culture of integrity, since the early days of my career, and I am looking forward to serving as its chairman now.”

About Koh Boon Hwee

Koh is managing director of Credence Capital Fund II (Cayman) Ltd., a private equity fund. He currently serves as the non-executive chairman to Sunningdale Tech Ltd., where he was previously the executive chairman and CEO. He has also served as chairman at DBS Bank Ltd., Singapore Airlines and Singapore Telecom. Earlier in his career, Koh spent 14 years with Hewlett-Packard Co. in its Asia Pacific region. He is a graduate of Imperial College of Science and Technology, London, and Harvard Business School.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A), a global leader in life sciences, diagnostics and applied chemical markets, is the premier laboratory partner for a better world. Agilent works with customers in more than 100 countries, providing instruments, software, services and consumables for the entire laboratory workflow. The company generated revenues of $4.20 billion in fiscal 2016 and employs about 12,500 people worldwide. Information about Agilent is available at www.agilent.com.

EN
15/03/2017

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Agilent Technologies Inc.

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

 PRESS RELEASE

Agilent xCELLigence RTCA Instrumentation Applied in Recent FDA Approva...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- (NYSE: A) is pleased to announce its role in supporting Autolus Therapeutics’ , a recently approved CAR T therapy. Agilent's advanced cell analysis instrumentation, specifically the technology, was applied in developing and validating AUCATZYL. The xCELLigence RTCA technology supported the development and implementation of the potency assay. By providing precise and reliable cell analysis solutions, Agilent assisted Autolus in achieving the high standards required for FDA approval. Dr. Xiaobo Wang, Vice President and General Manager of the Cell Functio...

 PRESS RELEASE

CORRECTING and REPLACING Agilent to Showcase Next-Generation Digital P...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- Please replace the release with the following corrected version due to multiple revisions to the fifth paragraph. The updated release reads: AGILENT TO SHOWCASE NEXT-GENERATION DIGITAL PATHOLOGY SOLUTIONS AT USCAP 2025 (NYSE: A) is excited to announce its participation at the upcoming , which will be held March 22-27, 2025, in Boston. At the conference, Agilent will highlight innovative digital pathology solutions designed to enhance diagnostic accuracy and efficiency. In pathology, Agilent offers comprehensive tissue diagnostic solutions for analyzi...

 PRESS RELEASE

Agilent Research Catalyst Award Presented to Columbia University for P...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- (NYSE: A) today announced that has received an Agilent Research Catalyst (ARC) Award on behalf of , an internationally recognized researcher and physician-scientist specializing in bone marrow transplant (BMT) and cancer cellular immunotherapy. Dr. Muranski is the Director of Cellular Immunotherapy Laboratory at Columbia University Irving Medical Center. He is also an Assistant Professor of Medicine at Columbia University Medical Center, a principal investigator at the Columbia Center for Translational Immunology (CCTI), and a member of the Herbert Irv...

 PRESS RELEASE

Agilent PD-L1 IHC 28-8 pharmDx Receives EU IVDR Certification as a Com...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- (NYSE: A) today announced its kit has received two new companion diagnostic indications approvals under EU IVDR1, expanding the eligibility of treatment to early-stage non-small cell lung cancer (NSCLC) and previously untreated advanced melanoma patients. These two new indications bring the total indications launched in Europe for PD-L1 IHC 28-8 pharmDx to nine. PD-L1 IHC 28-8 pharmDx is approved for exclusive use with the advanced staining solution. Lung cancer and malignant melanoma are major healthcare concerns worldwide, with lung cancer accountin...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch